Rapamycin extends mouse lifespan when started in late life
The Interventions Testing Program reports in Nature that rapamycin fed from about twenty months of age extends median and maximal lifespan in genetically heterogeneous mice at all three test sites. Starting the drug in middle-to-old age and still seeing an effect is what makes the result unusual and what made it the field's most cited pharmacological finding.
Historical — it happened, and the record is settled.
Subjects
- Rapamycin · technology · not located
- NIA Interventions Testing Program · research programme · United States · not located
Evidence
Partly verified — Core facts are sourced; some optional detail is deliberately absent.
Rapamycin fed late in life extends lifespan in genetically heterogeneous mice
Supports the late-life lifespan extension by rapamycin replicated across the Interventions Testing Program's three sites. V55 verification basis: not retrieved; the specific percentage extensions and the sex difference are unchecked and are therefore not quoted numerically in the objects citing this record.
Nature · 2009 · Partly verified
Harrison D.E. et al. for the NIA Interventions Testing Program, Nature, vol. 460, 2009
Recorded on Rapamycin
- The NIA Interventions Testing Program begins
- Rapamycin extends mouse lifespan when started in late life
Related
Related because they share a subject in the Atlas — never because the text looks similar.